We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Scientific title
A randomised controlled trial of Docetaxel plus Carboplatin as neo-adjuvant versus adjuvant chemotherapy treatment in stage IB to IIIA non-small cell lung cancer (NSCLC) to improve disease free survival
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small cell lung cancer 1180 0
Condition category
Condition code
Cancer 1263 1263 0 0
Lung - Non small cell

Study type
Description of intervention(s) / exposure
Patients with operable stage IB to IIIA NSCLC were randomised either to radical resection followed by three cycles of TP (Arm A) or three cycles of TP followed by radical resection (Arm B). Arm A: post-operative chemotherapy(adjuvant) Arm B: pre-operative chemotherapy(neo-adjuvant)TP regimen: Docetaxel: 75 mg/m², day 1 intravenous for1 hour, Carboplatin : AUC 5 , day 1 intravenous for 1 hour, Treatment is repeated every 3 weeks for a total of 3 cycles. All randomised patients who do not receive resection will be recommended to receive relevant treatment in line with National Comprehensive Cancer Network (NCCN) guideline.
Intervention code [1] 1009 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 1701 0
3 years Disease Free Survival
Timepoint [1] 1701 0
At the end of 3 years
Secondary outcome [1] 3052 0
3 years Overall Survival rate
Timepoint [1] 3052 0
At end of 3 years
Secondary outcome [2] 3053 0
Safety data
Timepoint [2] 3053 0
After third cycle finish

Key inclusion criteria
Histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer patients,without previous chemotherapy, radiotherapy or target-therapy; PS with ECOC 0-1; Adequate haematological and Hepatic- renal function; Expected live longer than 12monthes; The informed consent should be signed.
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Patients with Small Cell Lung Cancer; Already receiving any prior anti-cancer treatment; Pregnant woman;With uncontrol diabetes, mental disease; Hepatic and renal function failure,The investigators believe the patients is not suitable to be enrolled in the study.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone/FAX
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Dynamic random allocation with minimization
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 305 0
State/province [1] 305 0

Funding & Sponsors
Funding source category [1] 1381 0
Name [1] 1381 0
Chinese Society of Lung Cancer
Address [1] 1381 0
Country [1] 1381 0
Funding source category [2] 1382 0
Name [2] 1382 0
Guangdong Provincial People,s hospital
Address [2] 1382 0
Country [2] 1382 0
Primary sponsor type
Chinese Society of Lung Cancer
Secondary sponsor category [1] 1217 0
Name [1] 1217 0
Address [1] 1217 0
Country [1] 1217 0

Ethics approval
Ethics application status
Ethics committee name [1] 2733 0
Guangdong Provincial People's Hospital
Ethics committee address [1] 2733 0
Ethics committee country [1] 2733 0
Date submitted for ethics approval [1] 2733 0
Approval date [1] 2733 0
Ethics approval number [1] 2733 0

Brief summary
Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers diagnosed worldwide. Surgical resection offers the best chance for cure for those patients diagnosed with early-stage disease, however, the vast majority of patients experience eventually relapse or metastasis. The rationale of neoadjuvant or adjuvant chemotherapy for early stage NSCLC lies in the possibility of eradicating micro-metastasis disease, so it appears to improve survival by reducing the occurrence of distant metastases. Meta analysis, CALGB 9633, JBR 10 and ANITA trials have shown postoperative (adjuvant) CT after complete resection will prolong survival. On the other hand, Depierre et al had conducted a trial to demonstrate preoperative (neoadjuvant ) chemotherapy in early stage NSCLC appears to improve survival. We need a head to head trial to comparing neoadjuvant with adjuvant chemotherapy to answer which treatment model is better to early stager NSCLC. Based on proven activity and survival benefit in advance NSCLC, docetaxel has been introduced into neoadjuvant therapy, even as a potential option in adjuvant setting. The objective of the trial is to determine whether 3 cycles of TP after complete operation will improve survival when compared with 3 cycles of TP prior to complete resection for NSCLC.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 36181 0
Address 36181 0
Country 36181 0
Phone 36181 0
Fax 36181 0
Email 36181 0
Contact person for public queries
Name 10198 0
Yi-long Wu
Address 10198 0
Guangdong Provincial People's Hospital
106 Zhongshan Er Road
Guangzhou 510080
Country 10198 0
Phone 10198 0
+86 20 83877855
Fax 10198 0
Email 10198 0
Contact person for scientific queries
Name 1126 0
Xiao-song Ben
Address 1126 0
Guangdong Provincial People's Hospital
106 Zhongshan Er Road
Guangzhou 510080
Country 1126 0
Phone 1126 0
+86 20 83877855
Fax 1126 0
Email 1126 0

No information has been provided regarding IPD availability
Summary results
No Results